The complement regulatory protein CD59 inhibits formation of the membrane attack complex (MAC), the terminal effector of the complement system. There are two mouse Cd59 genes in mice but only one in humans. In the work reported here we (a) mapped the promoter regions of both mCd59a and mCd59b genes, (b) identified two different promoters for each mCd59 gene, (c) defined a previously unrecognized additional exon 1 in each mCd59 gene, (d) identified that each mCd59 gene expresses two different tissue-specific transcripts that differ in their 5 0 -UTR, and (e) confirmed the presence of mCd59b mRNA in multiple tissues. At the functional level, comparison of the sensitivity of mCd59ab À/À and mCd59a À/À red blood cells to MAC-mediated lysis revealed that mCd59b protects RBC from MAC-mediated lysis, at least in the setting of mCd59a deficiency. Together these findings indicate that the mCd59 genes may have complex and perhaps different regulatory mechanisms in different tissues.
Introduction
The complement system, an effector of both adaptive and innate immunity, is composed of more than 30 plasma and cell-membrane proteins that interact with one another in three enzymatic activation cascades known as the classical, alternative, and lectin pathways. Activation through either pathway eventually leads to the generation of the membrane attack complex (MAC), a macromolecular pore that can lead to colloid-osmotic swelling and lysis of the target cell. In autologous cells, MAC pores can be formed and closed transiently, generating significant changes in membrane permeability and internal composition without compromising the cells' viability.
1,2 Insertion of these transient MAC pores into endothelial cell membranes results in an array of cellular responses that can induce cell proliferation, inflammation and thrombosis, as seen in all diseases in which focal complement activation is a characteristic pathological abnormality (reviewed in Acosta et al. 3 ). CD59 is a glycan phosphatidylinositol (GPI)-linked complement regulatory membrane protein ubiquitously expressed in most cells. Functionally, CD59 restricts formation of the terminal complement MAC by preventing C9 incorporation and polymerization. 4, 5 The importance of CD59 in protecting 'self' cells from the deleterious effect of unrestricted MAC attack is highlighted by the human disease paroxysmal nocturnal hemoglobinuria (PNH). In the PNH disease, the absence of GPI-linked proteins, including CD59, in bone marrow precursors leaves circulating blood cells such as erythrocytes and platelets unprotected from even baseline 'tickover' complement attack resulting in complementmediated hemolytic anemia and thrombosis. 6 Conversely, transgenic expression of human CD59 in pigs protects porcine xenografts from complement attack and prolongs graft survival in cardiac transplant animal models. 7, 8 Several lines of evidence indicate that CD59 is more relevant than other complement regulators in protecting cells from MAC formation. In humans, an isolated deficiency of decay accelerating factor (DAF) described in four families did not result in a PNH phenotype although it was totally absent on all circulating cells. 9, 10 In contrast, an index subject with a global deficiency of CD59 reportedly expressed a severe PNH phenotype since the unusually young age of 13, and suffered a stroke when he was 19 years old. 11 In animals, a DAF knockout mouse did not show any evidence of intravascular hemolysis, whereas the targeted deletion of CD59 resulted in a PNH-like phenotype with hemolysis and spontaneous platelet activation. [12] [13] [14] As unrestricted MAC insertion activates multiple cellsignaling pathways that induce proliferation, inflammation, and thrombosis, and CD59 restricts MAC formation, absence or disfunction of CD59 in tissues other than blood cells may play a pathogenic role in some human diseases. 15, 16 For example, we have shown that inactivation of CD59 by non-enzymatic glycation of its K41 residue causes increased MAC deposition, and that glycated CD59 colocalizes with MAC in human diabetic kidneys and nerves, two critical target tissues of diabetic complications. 17 Functionally, we have shown that decreased activity of CD59 in diabetic erythrocytes is associated with increased sensitivity to MAC-mediated lysis, 17 a similar result to that reported by Davies et al. 18 Given the intrinsic difficulties in comprehensively studying the role of human CD59 in the pathogenesis of human disease, there is a strong need for an appropriate mouse model. For this reason, we decided to generate mice with either a loss (targeted deletion) or gain (transgenic expression) of CD59 function. This task has been complicated by the finding that mice have two CD59 genes, termed mCd59a and mCd59b, whereas there is only one CD59 gene in humans. [19] [20] [21] In both genes, the first exon contains only 5 0 -untranslated region (5 0 -UTR), the second exon contains the remainder of the 5 0 -UTR and the beginning of the coding sequence, and the third and fourth exons contain the rest of the coding sequence and the 3 0 -untranslated regions. 20 The elucidation of the mouse Cd59 genomic structure allowed the targeted deletion of the Cd59 genes. 21, 22 Holt et al. generated mCd59a
, which show spontaneous intravascular hemolysis with increased free hemoglobin in the plasma.
14, 23 We developed mCd59b knockout (mCd59b
), 13 and mCd59a and mCd59b double knockout (mCd59ab À/À ) mice (paper in preparation). Interestingly, mCd59b À/À mice show spontaneous hemolytic anemia and spontaneous platelet activation (PNH-like phenotype), 13 a finding that generated some controversy fueled in part by the report by Harris et al. concerning wild type mice, in which 'all blood cell types were uniformly negative for mCD59b as assessed by flow cytometry following staining with mCD59b.1 mAb'. 24 However, using 'new specific reagents', this group later confirmed the presence of mCd59b in erythrocytes and suggested that mCd59a accounted for most of the protection afforded to mouse RBC against mouse complement-mediated hemolysis, 25 a conclusion contradicted by the strong phenotype in mCd59b À/À . 13 Here we report the downregulation of mCd59a in mCd59b À/À mice, which probably contributes to the strong PNH-like phenotype of mCd59 À/À mice. 13 The presence of two mCd59 genes with different functional and expression levels together with our demonstration that human but not mouse Cd59 is inhibited by glycation, indicate that a mCd59ab À/À mouse that transgenically expresses hCD59 at levels similar to those of the mouse protein would represent a valuable animal model to study the role of complement and CD59 in some prevalent human diseases, including diabetes and atherosclerosis. Generation of such a mouse model requires the analysis of the elements that control transcription of both mCd59a and mCd59b in order to produce a transgenic mouse expressing hCD59 under the control of the mCd59a or mCd59b promoter. To this end, we mapped the mCd59a and mCd59b promoter regions and found that both genes are controlled by two different promoters in a tissue-specific manner.
Results
Promoter mapping of mCd59a and mCd59b Previously, we demonstrated that the first exons in the two mCd59 genes (63 bp in mCd59a, and 78 bp in mCd59b, hereafter termed exon 1 mCD59a and exon 1 mCD59b ) have dissimilar sequences. 19, 20 In order to determine the location of functionally essential sequences required for maximal promoter activity of mCd59a or mCd59b, we mapped the promoter regions by deletion analysis combined with luciferease gene reporter assays in NIH 3T3 cells. Several luciferase reporter constructs were generated by inserting different fragments of mCd59a or mCd59b genomic DNA into a pGL3-basic vector upstream from the firefly luciferase reporter gene; in both cases the mCd59 genomic DNA inserts were from sequences upstream of exon 1 of the respective mCd59 gene (Figure 1 ). Promoter activities were assessed by transient transfection of 3T3 cells followed by dualluciferase assay measurements of firefly luciferase (experimental) and renilla luciferase (internal control) activities. Figure 1a shows that several regions located upstream of the transcription start site of mCd59a 19, 21 (Gene accession no. AF292401) such as bp À2958 to þ 45, À366 to þ 45, À266 to þ 45, À199 to þ 45 and À122 to þ 45 but not the regions from bp À2958 to À333 or À35 to þ 45 exert strong promoter activity. This indicates that the core promoter for the transcription of the mCd59a resides in the region of bp À122 to À36 (black circles, Figure 1a ). The highest promoter activities (firefly over renilla luciferase ratio X20) were observed with the inserts spanning bp À266 to þ 45, À199 to þ 45 and À122 to þ 45. Intermediate promoter activities (ratio of 10 to 20) were observed with the inserts spanning bp À2958 to þ 45 and À366 to þ 45, suggesting the presence of minor silencers in the areas between bp À2958 and À267. Figure 1b shows that several regions located upstream of the transcription site of mCd59b 20 such as bp À1832 to þ 14, À1128 to þ 14, À554 to þ 14, À370 to þ 14 and À198 to þ 14 but not in regions from bp À1832 to À299 to À145 to þ 14, exert strong promoter activity. These results indicate that the core promoter for the mCd59b transcript resides in the region from bp À198 to À146. The reduced promoter activity seen in constructs containing bp À554 to þ 14, À370 to þ 14 and À198 to þ 14, suggests the presence of enhancers in the area between bp À1832 to À555. These upstream regulatory elements require the presence of core promoter to display their activity.
Together, the results depicted in Figure 1 show that the bp À122 and À36 and the bp À198 and À146, regions, respectively contain the core promoters of mCd59a and mCd59b.
Electrophoretic mobility shift assay (EMSA) Next, we performed EMSA to test whether the bp À122 and À36 and the bp À198 and À146 core promoter regions of mCd59 genes (Figure 1a and b) can bind to the nuclear proteins that contain transcriptional factors. Figure 2a and b show that nuclear proteins from mouse 3T3 cells specifically bind to the DNA fragments bp À122 to þ 45, which exhibits strong promoter activity in the mCd59a promoter analysis (Figure 1a ). In contrast, these nuclear proteins did not bind bp À35 to þ 45, which has no promoter activity as shown in Figure 1a . Figure 2c and d show that the nuclear proteins also bind to the DNA fragments bp À370 to þ 14, which exhibits strong promoter activity in mCd59b promoter analysis ( Figure 1b ). These nuclear proteins did not bind to bp À145 to þ 14, which has no promoter activity, as shown in Figure 1b . The reason to select DNA fragment bp À370 to þ 14 instead of À198 to þ 14 was that the first has significantly higher promoter activity than the second (Figure 1b ) in the mCd59b reporter gene assay. In summary, these results indicate that some unidentified transcriptional factors from cell nuclear proteins may specifically bind the core promoter region of mCd59a (bp À122 and À36) or mCd59b (bp À198 and À146). There experiments set the stage for further identification of the key transcriptional regulatory elements that regulate the expression of these genes.
Two different 5
0 -untranslated regions (5 0 -UTR) in both mCd59a and mCd59b mCd59b. We have previously reported the presence of mCd59b mRNA in different tissues, 21 a finding disputed by Baalasubramanian et al. 25 We reasoned that the presence of mCd59b in tissues other than testes and bone marrow could be investigated by a mouse expressed sequence tag (EST) database search. A BLAST EST database search using the whole mouse mCd59b cDNA sequence 20 found that several ESTs from different tissues matched the mCd59b sequence with over 97% similarity in the region of exons 2 to 4. In contrast, the region corresponding to exon 1 mCd59b in different ESTs showed no homology with the mCd59b sequence used for the search. Surprisingly, the putative exon 1 in the mCd59b EST sequences (hereafter termed exon 1 0 mcd59b ) was identical to exon 1 mCd59a (Figure 3a) . These findings (a) confirm the presence of mCd59b mRNA in tissues other than testes and (b) suggest that the mCd59b gene may contain an additional exon 1 (exon 1 0 mCd59b ) (Figure 3a) . Figure 1 Promoter analysis of mCd59a (a) and mCd59b (b). The lines represent the size of various genomic fragments upstream from the exon 1 region of either mCd59a (Gene accession no. NM_007652) or mCd59b (Gene accession no. NM_181858) inserted into the pGL3 basic vector to control reporter gene expression as measured by firefly luciferase (luc) activity. The location of the transcription start site is described as þ 1. Numbers on both ends of the lines show the positions of the ends of the genomic fragments. Transfection efficiency was determined by cotransfection with the vector, which expresses renilla luciferase under the control of the thymidine kinase promoter. The promoter activity results (black bars) were normalized to the activity of the internal renilla luciferase control present in all constructs. Promoter activity is defined as the ratio of firefly luciferase activity to renilla luciferase activity. pGL3 represents the baseline promoter activity for the pGL3 basic vector without the insertion of genomic fragments. The black circles indicate the core promoter regions. Bars represent mean7s.e.m. of the experiment done in triplicate. *Po0.001 (promoter activity of genomic fragments compared to baseline promoter activity of pGL3 vector alone by Student's t-test).
To test this prediction, we used the 5 0 -RACE technique with a specific mCd59b reverse primer that recognizes the exon 4 region in mCd59b mRNA and the GeneRacert 5 0 -primer to amplify the 5 0 -end of mCd59b from mouse testes cDNA. This experiment confirmed the existence of an isoform of mCd59b RNA that contains a novel 5 0 -UTR (exon 1 0 mCd59b ), which is 100% similar to exon 1 mCd59a as reported in 19 ( Figure 3a ). Thus, a novel mCd59b transcript is encoded by 4 exons: exon 1 0 mCd59b , and the originally published exons 2, 3 and 4 of mCd59b. 20 In our original report of the mCd59 genomic sequence we did not identify the exon 1 0 mCd59b sequence because the 47 kb region analyzed did not include this newly identified exon 1 0 mCd59b . 21 To confirm this interpretation, we sequenced the BAC that contains the mCd59 gene with the same primer walking strategy previously described, 21 and extended the genomic sequence an additional 775 bp upstream from the 5 0 -end of the reported mCd59b genome (Genbank no. AF292401). This extended DNA fragment covers exon 1 0 mCd59b , which resides in the region 1087 bp upstream from the original exon 1 mCd59b (Figure 4c) .
A BLAST search of the EST mouse database with the sequence of the new mCd59b transcript documented its presence in multiple tissues including liver (AA268823), brain (BU555124 and BU530131), mammary gland (AA575237 and AI019497), early embryonic tissues (BY448425), bone marrow (BY226453), and testes (AV047071). To confirm this finding experimentally, we performed RT-PCR with a forward primer derived from exon 1 0 mCd59b and the mCd59b specific reverse primer previously used to amplify mCd59b, as described above. Figure 3c (right panel) shows that the new mCd59b isoform is present in multiple tissues of wild-type mice. Confirming the specificity of our primers, mCd59b transcripts were not found in tissues derived from mCd59b À/À mice. Furthermore, RT-PCR with a forward primer derived from exon 1 mCd59b and the same mCd59b specific reverse primer showed that mCd59b transcripts containing exon 1 mCd59b are only present in testes ( Figure 3d ). Together, these data suggest that there are two different isoforms of mCd59b that contain the same second, third, and fourth exons but differ in their first exon. It appears that (a) the distribution of these two mCd59b isoforms is tissue-specific, (b) the isoform containing exon 1 mCd59b is testes specific, and (c) the isoform containing exon 1 0 mCd59b is expressed in both testes and other tissues. mCd59a. We have previously reported that the sequence of exon 1 mCd59b is also present between exons 1 and 2 of the mCd59a genomic sequence; 21 this suggests that the mCd59a gene may have two different transcripts containing different first exons (hereafter termed exon 1 mCd59a and exon 1 0 mCd59a , see Figure 3a and b). To test this prediction, we performed RT-PCR with a forward primer identical to exon 1 mCd59b and a specific reverse primer derived from exon 4 of mCd59a (Figure 3d ). Figure 3d shows that the exon 1 mCd59b forward/mCd59a exon 4 specific reverse primer pair amplified multiple RT-PCR products in testes but not in other tissues such as fat tissue, brain, liver, or kidney, a distribution similar to that of the mCd59b transcript containing exon 1 mCd59b . These results suggest that similar to mCd59b, mCd59a may also have two different transcripts that contain two different first exons and the same second, third, and fourth exons of mCd59a. Sequencing of the RT-PCR products demonstrated that there is 97% similarity between exon 1 0 mCd59a and exon 1 mCd59b (Figure 3b ). Exon 1 0 mCd59a resides in the region 1113 bp downstream from exon 1 mCd59a (Figure 4d ). Consistent with our previous report, 21 RT-PCR with an exon 1 mCd59a -derived forward primer and a specific reverse primer derived from exon 4 of mCd59a amplified mCd59a from multiple tissues' Promoter Analysis of Mouse Cd59 Genes X Qin et al cDNAs (left panel, Figure 3c ). Thus, it appears that similar to mCd59b, there are two isoforms of mCd59a that are tissue specific with the isoform containing exon 1
expressed only in testes, and the isoform containing exon 1 mCd59a expressed in both testes and other tissues (Figure 3 ).
Alternative splicing of the testes-specific mRNA isoforms of mCd59a and mCd59b. Cloning and sequencing of the multiple RT-PCR products of mCd59a and mCd59b shown in Figure 3d demonstrated that there are three different RT-PCR products for mCd59b containing exon 1 mCd59b and two isoforms of mCd59a containing exon 1 0 mCd59a . These mCd59b and mCd59a isoforms share the same respective 5 0 -UTR suggesting that they result from alternative splicing (Figure 3d ). The longest isoform of mCd59b contains exon 1 mCd59b with an adjacent 182 bp downstream extension (Figure 4a ), plus exons 2, 3, and 4 of mCd59b. The middle-length isoform of mCd59b is similar to the longest isoform, but with a 75 bp fragment spliced out downstream of the 3 0 -end of exon 1 mCd59b (non-underlined sequence, Figure 4a ). The smallest isoform contains exon 1 mCd59b plus exons 2, 3, and 4, and is the same isoform we reported previously. 20 There are two different RT-PCR products for the testesspecific form of mCd59a that contains exon 1 (Figures 4b and d) . The smaller isoform contains exon 1 0 mCd59a plus exons 2, 3, and 4 of mCd59a. In summary, each one of the two mCd59 genes expresses two different mRNA species that differ in their 5 0 -UTR. In both cases there is one transcript expressed in multiple tissues including the testes, and another transcript expressed only in the testes. These two isoforms of either mCd59 gene may result from either alternative splicing of pre-mRNA or different transcription start sites under the control of different promoters. The possibility that each one of the mCd59 genes is controlled by two different promoters is supported by the high similarity between the promoter region upstream of exon 1 mCd59b (described in Figure 1b ) and the genomic sequence upstream of exon 1 0 mcd59a (termed the potential second mCd59a promoter) (Figure 5a) , and by the similarity between the promoter region upstream of exon 1 mCd59a (described in Figure 1a ) and the genomic sequence upstream of exon 1 0 mCd59b (termed potential second mCd59b promoter) (Figure 5b ). In the testesspecific isoforms, the similarity between the established core promoter region of mCd59b (bp À198 to À146) and the potential second mCd59a promoter region (bp À203 to À151 of mCd59a) is 100% (Figure 5a ). In the isoforms present in both testes and other tissues, the similarity between the established core promoter region of mCd59a (bp À122 to À36, Figure 1 ) and the potential second mCd59b promoter region (bp À121 to À35 of mCd59b) is 89% (Figure 5b ). In addition, the similarity between the approximate 1 kb sequences upstream of the mCd59b core promoter (Figure 5a , upper sequence) and of the potential second mCd59a promoter (Figure 5a , lower sequence) is 83%. The similarity between the approximate 700 bp sequences upstream of the mCd59a core promoter (Figure 5b , upper sequence) and of the potential second mCd59b promoter (Figure 5b , lower sequence) is 52%.
Two promoters for mCd59a and mCd59b To confirm that the potential second promoter regions of mCd59a (À203 to À151) and mCd59b (À121 to À35) do have promoter activity, we used the dual luciferease gene reporter assay to assess the promoter activities of DNA fragments covering these potential promoter regions, following a strategy similar to the one depicted in Figure 1 . Specifically, we used the genomic DNA fragment bp À788 to þ 19 based upon a transcription start site at the exon 1 Figure 5c , both DNA fragments exhibited significant promoter activity. Based on the location of the potential second promoters that we predicted and the results of the reporter gene experiment, we conclude that each one of the mCd59 genes has two promoters. For each gene, both promoters control the transcription of two different mRNA, which differ in their 5 0 -UTRs.
Downregulation of mCd59a in mCd59b
À/À and functional mCd59b activity in mouse RBC mCd59b À/À mice express a strong PNH-like phenotype, as we previously reported. 13 To assess the relative distribution of the mCd59 genes in mouse RBC, we performed FACS analysis using new anti-mCd59a and mCd59b monoclonal antibodies kindly provided by Dr BP Morgan. The results shown in Figures 6a and b confirmed the presence of mCd59b in mouse RBC and revealed that mCd59a is significantly downregulated in mCd59b À/À RBC. The mean fluoresce density of mCd59a in mCd59b À/À 's and in mCd59 þ / þ 's RBC was 4.5 and 34, respectively. The mean fluoresce density of mCd59b and mCd59a in mCd59 þ / þ 's RBC was 4 and 34, respectively. In contrast to the downregulation of mCd59a in mCd59b À/À mice, there is no downregulation of mCd59b in mCd59a À/À RBC, as reported by Baalasubramanian et al. 25 As in mRBC mCd59b is expressed at a E10-fold lower density than mCd59a (Figure 6a ), 25 it was important to assess directly the relative function of both mCd59 proteins in mRBC. To this end, we used the MAC-specific assay (C5b7 site assay with mouse serum-EDTA as a source of C8 and C9) 19, 13 ) to compare mouse complement-mediated hemolysis in RBC from mCd59
À/À (kindly provided by BP Morgan), and mCd59ab À/À generated by us (manuscript in preparation). RBC represents the specific functional activity of mCd59b in mouse RBC (Figure 6d ). In summary, partial downregulation of mCd59a and deficiency of mCd59b activity may explain the strong PNH-phenotype of mCd59b À/À mice.
Discussion
In the work presented here we have (a) mapped the promoter region of both mCd59a and mCd59b genes, (b) documented the presence of two different promoters for each mCd59 gene, (c) found that both genes have a previously unrecognized additional exon 1, and (d) identified that each mCd59 gene expresses two different tissue-specific transcripts that differ in their 5 0 -UTR. The two core promoters of each mCd59 gene reside approximately 200 bp immediately upstream from the transcription start site, which is similar to the location of the single promoter of human CD59 that resides in the first 70 bp immediately upstream from the transcription start site. 26, 27 The biological and evolutionary significance of the two promoters in the mCd59 genes is not presently clear. In practical terms, this new information on the regulatory elements of the mCd59 genes provides the necessary preliminary information for the generation of human CD59 transgenic mice in which the transgene is under the control of the mCd59 promoter and is expressed at a similar physiological level to mCd59 in mice, key aspects for the development of a much-needed animal model to study the role of complement in human diseases, including the vascular complications of diabetes. Of note, the fragment between bp À1832 and À299 upstream of the exon 1 mCd59b shown in Figure 1b , displays minimal promoter activity by itself. This would have been expected if the only transcript resulting from this fragment were mCd59b with its exon 1. This is because the core promoter for mCd59b transcript containing exon 1 mCd59b is downstream from bp À299. However, the mCd59b transcript containing exon 1 0 mCd59b and its core promoter reside within this fragment (bp À1832 and À299), as shown in Figure 5c . This suggests that the fragment À1832 to À299 should express promoter activity but this is not evident in the reporter gene assay (Figure 1b) Figure 5 Two promoters for mCd59a and mCd59b. (a) Sequence similarity between the established core promoter region of mCd59b (bp À198 to À146) and the potential second mCd59a promoter region (bp À203 to À151 of mCd59a). The location of the transcription start site of the novel isoform of each mCd59 gene that contains the exon 1 0 in each gene is described as þ 1. (b) Sequence similarity between the established core promoter region of mCd59a (bp À122 to À36) and the potential second mCd59b promoter region (bp À121 to À35 of mCd59b). (c) Confirmation of the promoter activities of the potential second mCd59a and mCd59b promoter regions. Negative: the known fragment that does not have promoter activity as shown in Figure 1a ; Positive A: the known fragment that has promoter activity as shown in Figure 1a ; Positive B1 and B2: the known fragments that have the promoter activity as shown in Figure 1b ; (a) the genomic fragment bp À788 to þ 19 that contains the potential second mCd59a promoter region (bp À203 to À151 of mCd59a); and (b) the genomic fragment bp À364 to þ 22 that contains the potential second mCd59b promoter region (bp À121 to À35 of mCd59b). Bars represent mean7s.e.m. of the experiment done in triplicate. *Po0.001 (promoter activity of genomic fragments compared to baseline promoter activity of pGL3 vector alone by Student's ttest). The black circle represents the core promoter region (as described in Figure 1a) ; white circles represent the promoter region that shows promoter activity for the second potential promoter region of each mCd59 gene.
Promoter Analysis of Mouse
0 -UTR that is approximately 1 kb-long in front of the reporter gene. Such a long 5 0 -UTR would dramatically reduce the translation efficiency of the reporter. Second, the transcript resulting from such a promoter may not yield a mature reporter mRNA because the transcript is not properly processed. For example, the transcript may contain an upstream splice donor but not a downstream splice acceptor. This work also helped clarify some contradictory results regarding the presence of mCd59b in tissues other than testes, where it was originally detected. 21 Recently, Baalasubramanian et al. reported that they, 'consistently failed to PCR amplify mRNA encoding mCd59b from any mouse tissue except testes'. 25 To clarify this point we searched EST databases and found the presence of mCd59b EST in multiple tissues, including liver, brain, mammary gland, early embryonic tissues and testes. Furthermore, we experimentally confirmed the expression of mCd59b mRNA in multiple tissues by RT-PCR (right panel, Figure 3c) , and sequenced the RT-PCR products to document the specificity of the primers used. An analysis of the primers reportedly used by Baalasubramanian et al.'s in their PCR experiment, 25 identified two mismatches, one in the forward (5 0 -GCCGGAA[T]GCAAGTGTATCA-3 0 ) and one in the reverse (5 0 -GTCCCCAGCAATG[G]TG TCTT-3 0 ) primer used by the authors 25 and the corresponding mCd59b sequence, which the primers were supposed to identically match (the brackets identify the corresponding mismatches). In contrast, both primers perfectly matched their corresponding sequences in mCd59a. Owing to these mismatches with the mCd59b sequence, one would anticipate that the primer pair used by Baalasubramanian et al. 25 would preferentially amplify mCd59a over mCd59b, a possible explanation for their failure to quantitatively estimate levels of mCd59b mRNA by real-time PCR in tissues other than testes and bone marrow.
At the protein level, we have confirmed the physical presence of mCd59b on mRBC by FACS analysis. Moreover, by comparing mouse MAC-mediated lysis in mCd59ab À/À and mCd59a À/À RBC, we provided a semiquantitative estimate of the protective function of mCd59b, which in the absence of mCd59a confers a significant level of protection against mouse MACmediated lysis that is evident in the setting of mCd59a deficiency. The relative activities of both proteins in wildtype mRBC in vivo and in the absence of any manipulation are impossible to assess. Here, we also used more specific reagents to document a previously unidentified downregulation of mCd59a protein in mCd59b À/À mice (Figure 6b) , an observation consistent with the reduced tissue expression of mCd59a mRNA we have reported in mCd59b À/À (Figure 6 in  13 ) . The underlying cause of this downregulation is not yet understood. In practical terms, the mCd59b À/À mouse resembles a mCd59a and mCd59b partial double knockout, explaining the strong PNH-like phenotype of these mice.
Deleting the genomic region surrounding exon 3 of mCd59b was not expected to result in the downregulation of mCd59a. Several possibilities that could explain this phenomenon include: (a) the truncated protein generated in the mCd59b À/À mouse interferes with the transcription and/or translation of mCd59a, (b) the deleted region encompassing exon 3 of mCd59b (which is upstream from mCd59a) contains a long-region regulatory element that influences the transcription of mCd59a, or (3) insertion of the neo-gene in the reverse direction influences gene transcription downstream. Independent of the mechanism, it is very likely that the functional deficiency of Together the findings reported here confirm the presence of mCd59b mRNA in multiple tissues and indicate that it is functionally active, at least in mRBC in the setting of mCd59a deficiency. They also suggest that the mCd59 genes may have complex and perhaps different regulations in different tissues.
Materials and methods
The following animal studies have all been reviewed and approved by the Harvard Medical School Institutional Animal Care and Use Committee (Animal Welfare Assurance no. A3431-01; IACUC approval date: 1/10/05).
Construction of plasmids for promoter assays DNA fragments for insertion into the reporter vector were generated by PCR using template DNA -purified from the bacterial artificial chromosome (BAC) clone and previously proven to cover the mCd59a and mCd59b genomic sequences 21 -and primers that contain specific restriction sites on both ends (Table 1) . Thereafter, the location of the respective transcription start site of each gene is described as þ 1. High fidelity polymerase (Invitrogen, Carlsbad, CA, USA) with proofreading activity was used to minimize errors in amplification. Amplified fragments were inserted into the vector pGL3-basic (Promega, Madison, WI, USA) upstream of the firefly luciferase gene in the forward direction. Constructs were propagated in the XL-1 blue strain of Escherichia coli, and plasmid DNA was purified using Qiagen Mini columns (Qiagen, Valencia, CA, USA). The identity of DNA fragments in all the plasmids were verified by DNA sequencing.
Cell transfection and reporter gene expression assays
The NIH 3T3 (ATCC, Manassas, VA) cell line was maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% calf serum, 2 mM L-glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin. Transient transfection was performed by Effectene Transfection kit (Qiagen). Cells were divided into 24-well plates (6 Â 10 5 cells per well) and transfected 1 day later with 1 mg of the DNA construct to be tested. Transfection efficiency was determined by cotransfection with 5 ng of the vector pRL-TK (Promega), which expresses renilla luciferase under the control of the thymidine kinase-promoter. Dual-luciferase assays were carried out 48 h after transfection using a dualluciferase kit (Promega). Briefly, cells were harvested using passive lysis buffer, and 2 ml of cell extract was used to measure the activity of the two luciferases in the same assay. Promoter activity of each construct was normalized to the activity of the internal renilla luciferase control present in different constructs, namely, promoter activity is the ratio of firefly luciferase activity to renilla luciferase activity.
Electrophoretic mobility shift assay Nuclear extracts of mouse 3T3 cells were prepared using nuclear extract kit (active motive, Carlsbad, CA, USA). The DNA fragments with or without the core promoter regions of mCd59a or mCd59b ( Figure 1 ) were amplified by PCR with the corresponding primer pairs (Table 1) . Gel Shift Assay Systems (Promega, Madison, WI) was used to perform EMSA. Briefly, 20 000 cpm [g-32 P] ATPlabeled DNA fragments (7 nM) was used to bind with 8 mg nuclear extract, resolved on 4% polyacrylamide gels and detected by autoradiography. In competition experiments, unlabeled DNA (700 nM) was pre-incubated with 8 mg nuclear extract, and then labeled DNA was added.
5
0 -cDNA end-polymerase chain reaction (5 0 -RACE-PCR) Rapid amplification of 5 0 -cDNA end-polymerase chain reaction (RACE-PCR) was performed by the GeneRacert kit according to the manufacturer's instructions (Invitrogen). Briefly, 2 mg of total RNA was first treated with calf intestinal alkaline phosphatase and subsequently treated with tobacco acid pyrophosphatase. This procedure is designed to leave a 5 0 -phosphate moiety only on RNA that contain a cap structure, thus selecting for 5 0 -fulllength messages. This material was then joined to the Gene Racert 5 0 -RNA oligonucleotide (5 0 -CGACUGGAG bp À2958 to +45 (Figure 1a ) ataggtaccgagctcttagatgacaataaatgagcgagtta gccaagcttgatctcgagccctagacacttttcagatcgccagt bp À366 to +45 (Figure 1a) ataggtaccgagctcttaagtaggagcaagccacgatgtat gccaagcttgatctcgagccctagacacttttcagatcgccagt bp À266 to +45 (Figure 1a) ataggtaccgagctcttacaagagatagttctgggcactagca gccaagcttgatctcgagccctagacacttttcagatcgccagt bp À199 to +45 (Figure 1a) ataggtaccgagctcttataagaaatcagagggaaatgcaagc gccaagcttgatctcgagccctagacacttttcagatcgccagt bp À122 to +45 (Figure 1a) ataggtaccgagctcttaaggaaaaggcagtgactagaaggc gccaagcttgatctcgagccctagacacttttcagatcgccagt bp À35 to +45 (Figure 1a) ataggtaccgagctcttagctgtgtactgtcagcagtca gccaagcttgatctcgagccctagacacttttcagatcgccagt bp À2958 to +333 (Figure 1a ) ataggtaccgagctcttagatgacaataaatgagcgagtta gccaagcttgatctcgagcccgatatctttccaggccatacatcgt bp À1832 to +14 (Figure 1b) ataggtaccgacgcgttgaaaccaaacaaaatagatggc gccaagcttgatctcgagcccgtctggaagctaagtggcttaac bp À1128 to +14 (Figure 1b) ataggtaccgacgcgtgaaaagtgtatagtgcaggatctaa gccaagcttgatctcgagcccgtctggaagctaagtggcttaac bp À554 to +14 (Figure 1b) ataggtaccgacgcgtatcttttctccagttcttccggg gccaagcttgatctcgagcccgtctggaagctaagtggcttaac bp À370 to +14 (Figure 1b) ataggtaccgacgcgtggatgaaccagggatttagggtc gccaagcttgatctcgagcccgtctggaagctaagtggcttaac bp À198 to +14 (Figure 1b) ataggtaccgacgcgttctgaagtgcttatggagc gccaagcttgatctcgagcccgtctggaagctaagtggcttaac bp À145 to +14 (Figure 1b) ataggtaccgacgcgtaggggcctttccattgtga gccaagcttgatctcgagcccgtctggaagctaagtggcttaac bp À1832 to -288 (Figure 1b) ataggtaccgacgcgttgaaaccaaacaaaatagatggc gccaagcttgatctcgagccccgctactccacacctaaagtcc A (bp À788 to +19) (Figure 4c ) ataggtaccgagctcttaagctgctctagtggatatttttggtc gccaagcttgatctcgagccctcactttggatgtatcttgcttttta B (bp À364 to +22) (Figure 4c) ataggtaccgacgcgttggaactcagaaatcatgcctacctc gccaagcttgatctcgagcccagatcctgcactatacacttttca a
The location of the respective transcription start site of each gene is described as +1.
Promoter Analysis of Mouse Cd59 Genes X Qin et al CACGAGGACACUGACAUGGACUGAAGGAGUAGA AA) using RNA ligase. The ligated mRNA was then reverse-transcribed using Superscript II reverse transcriptase and random primers provided by the kit. A specific mCd59b reverse primer (5 0 -ATG AGG AAG 111 CTGCGTTG-3 0 ) that recognized a region in exon 4 of mCd59b and the GeneRacert 5 0 -primer (5 0 -CGACTG GAGCACGAGGACACTGA-3 0 ) were used to amplify the 5 0 -end of mCd59b from mouse testes cDNA. Polymerase chain reaction products were cloned into pCR4-TOPO vector for sequencing.
Reverse transcriptase (RT)-PCR By using the TRIzol reagent (Invitrogen), total RNA was isolated from different mouse tissues (liver, kidney, heart, bone marrow, fat tissue, testes) obtained from mCd59 þ / þ , mCd59a À/À , and mCd59ab À/À in C57BL6/svl29 mixed genetic background. Aliquots of these total RNAs (1 mg/each aliquot) were reverse-transcribed using random hexamers and avian reverse transcriptase according to the manufacturer's instructions (Invitrogen).
A forward primer that recognizes exon 1 0 of mCd59b (5 0 -AGTCACTGGCGATCTGAAAAG-3 0 ) and the specific mCd59b reverse primer described above were used to amplify mCd59b from multiple tissues' cDNAs. Even though this forward primer also recognizes exon 1 of mCd59a, no amplification of mCd59a occurred in the PCR reaction. The specificity of the amplification of mCd59b products was further confirmed by sequencing the RT-PCR products. A forward primer that recognizes exon 1 of mCd59a (5 0 -TGTCTAGAGCAGGATCTAGC-3 0 ) and a specific mCd59a reverse primer (5 0 -ATCCGTC AC 111 1GTT AC AC-3 0 residing in the exon 4 of mCd59a) were used to amplify mCd59a from multiple tissues' cDNAs. The specificity of the amplification of mCd59a products was further confirmed by sequencing the RT-PCR products.
A forward primer that recognizes exon 1 of mCd59b and also recognizes exon 1 0 of mCd59a (5 0 -GCTTCCA GACCTTGGTAAGTA-3 0 ) combined with either the specific mCd59b reverse primer described above or the specific mCd59a reverse primer described above were used to amplify mCd59b or mCd59a respectively from multiple tissues' cDNA.
Bacterial artificial chromosome (BAC) sequencing
Walking primers for extending the sequence upstream of mCd59 genomic sequences previously submitted (Genbank no. AF292401) were designed with primer design software. Primers were synthesized and used for further sequencing at the Tufts Core Sequencing Facility (Boston, MA, USA).
FACS analysis
The RBC from mCd59b þ / þ and mCd59b À/À in C57BL6/ svl29 mixed genetic background were incubated with anti-mCd59a or mCd59b specific monclonal antibodies 25 for 30 min at room temperature, washed three times with PBS/BSA (3%) buffer, and incubated for 30 min with a FITC-conjugated anti-mouse secondary antibody. The cells were washed in PBS three times before analyzing the fluorescence intensity using a FACScan (Becton Dickinson, Franklin Lakes, NJ, USA).
In vitro complement-mediated assays on mouse erythrocytes Sensitivity of mouse RBC to mouse complementmediated attack was assessed by a C5b-7 site assay with mouse serum as a source of C8 and C9 to form mouse MAC. 13 mRBC were sensitized with an anti-mouse CD24 IgM monclonal antibody(Research Diagnostics Inc., Flanders, NJ, USA), which recognizes the heat stable antigen (murine CD24), a GPI-linked glycoprotein highly expressed on erythrocytes. 28 Number of mice in each group was three.
